|3D model (Jmol)|| Interactive image|
|Molar mass||144.22 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Milacemide (INN) is an MAO-B inhibitor and glycine prodrug. It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease. Early clinical trials did not show positive results however, and the drug is now abandoned.
- "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
- "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
- Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.". Journal of the American Geriatrics Society. 40 (5): 503–6. PMID 1634705.
- Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X.